Storia in 3 fonti

J&J eyes rare disease expansion for blockbuster-to-be Imaavy with trial win

Last year, Johnson & Johnson arrived late to the party with Imaavy as the third FcRn blocker

Raccontata da

biopharmadive.com

fiercepharma.com

benzinga.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

fiercepharma.comStai leggendo1 mese fa

J&J eyes rare disease expansion for blockbuster-to-be Imaavy with trial win

Questo articolo riguarda un trial farmaceutico (J&J / Imaavy per malattia autoimmune rara) ed è completamente fuori scope per **Warptech Tech News**, che copre AI, tech, business e startup per manager IT/CTO italiani. Non è un pezzo che pubblicheremmo. Se hai articoli tech da riassumere, sono pronto.

originale

biopharmadive.com1 mese fa

J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch

J&J's Imaavy advanced for autoimmune hemolytic anemia; Beren Therapeutics secured $300M for Niemann-Pick disease therapy—rare-disease market remains well-funded. Orphan-drug unmet-need positioning and tax incentives drive sustained investor confidence; biotech slowdown hasn't dampened capital flow to premium-priced specialty therapies.

Timeline cronologica

giovedì 11 giugno 2026·biopharmadive.com
J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch
New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its…
giovedì 11 giugno 2026·fiercepharma.com
J&J eyes rare disease expansion for blockbuster-to-be Imaavy with trial win
Last year, Johnson & Johnson arrived late to the party with Imaavy as the third FcRn blocker

J&J eyes rare disease expansion for blockbuster-to-be Imaavy with trial win

Confronto fonti

J&J eyes rare disease expansion for blockbuster-to-be Imaavy with trial win

J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch

Timeline cronologica

J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch

J&J eyes rare disease expansion for blockbuster-to-be Imaavy with trial win

Johnson & Johnson Hits Goal With IMAAVY In Rare Blood Disorder - Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson Hits Goal With IMAAVY In Rare Blood Disorder - Johnson & Johnson (NYSE:JNJ)

EHA: J&J sharpens myeloma edge as Talvey, Darzalex Faspro combo proves its worth in earlier disease stage